Non-invasive method for detecting target rna
CA 2360997 A1 · Owner: Avi Biopharma, Inc. · Inventors: Iversen, Patrick L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method for targeting a particular mRNA sequence <i>in vivo</i> by oral administration of a morpholino antisense compound having uncharged phosphorus-containing backbone linkages. Also disclosed is a non-invasive method of detecting and quantitating the <i>in vivo</i> presence of RNA containing one or more selected target sequences. The method includes administering to a subject a nuclease-resistant antisense oligomer which hybridizes by Watson-Crick base pairing to a region of the target RNA with a Tm substantially greater than 37 ~C. The oligomer is able to complex intracellularly with target RNA and is release from intracellular , sites as a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.